India, June 3 -- Granules India Limited has announced that its wholly owned subsidiary, Granules Pharmaceuticals, Inc. (GPI), has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its manufacturing facility in Chantilly, Virginia, USA.
The facility was inspected by the USFDA between March 30 and April 3, 2026. Following the inspection, the regulator issued four observations in Form 483. The site has now received an EIR with a Voluntary Action Indicated (VAI) classification, indicating that while certain observations were noted, the agency does not currently recommend regulatory or enforcement action.
The Chantilly facility is an important part of Granules' global manufacturing and suppl...